Live Signals
Signals ScoreSignals Score (0–100) blends the three technical signals — MA, RSI and MACD — where BUY = 100, HOLD/NEUTRAL = 50, SELL = 0.
Each signal is weighted by its own historical BUY hit-rate for this ticker (a signal that has been right more often counts for more). Hit-rates from only a handful of past signals are pulled toward equal weight, so a small, noisy sample can't swing the score.
(18.75)
(17.55)
(13.65)
3 of 3 frames agree
Sessions where price opened above the prior high or below the prior low
| Date | Type | Gap % | Prev Close | Open | Filled? |
|---|---|---|---|---|---|
| 2026-11-12 | Gap Up | +0.67% | $122.27 | $123.09 | Filled |
| 2026-11-09 | Gap Up | +0.79% | $119.65 | $120.59 | Filled |
| 2026-11-06 | Gap Down | -1.38% | $118.01 | $116.38 | Filled |
| 2026-11-05 | Gap Up | +0.90% | $122.85 | $123.96 | Filled |
| 2026-11-02 | Gap Down | -1.14% | $120.39 | $119.02 | Filled |
| 2026-10-30 | Gap Up |
Candlestick patterns identified in recent price action
Bullish Engulfing
2026-11-11
A green candle fully engulfs the prior red candle. Buyers overwhelmed sellers in a single session — strong short-term reversal signal.
Support
Resistance
Stockasthics is an educational tool only. Nothing on this page constitutes financial advice. All signals, scores, and data are for informational and learning purposes only.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Official website ↗weekly
Signals from weekly candles smooth out daily noise and reveal the true intermediate trend. More reliable for direction. A BUY on the weekly carries more conviction than a daily BUY alone.
| +2.83% |
| $116.80 |
| $120.10 |
| Open |
| 2026-10-29 | Gap Down | -4.48% | $116.87 | $111.64 | Filled |
| 2026-10-27 | Gap Down | -1.88% | $113.31 | $111.18 | Filled |
Relative Strength vs SPY
RS: +22.29%
INCY: +19.4% vs SPY: -2.9% → RS: +22.3% Relative Strength = stock return minus index return over the same window. Positive = outperforming the market. Academic research (Jegadeesh & Titman 1993) shows stocks with strong relative momentum tend to keep outperforming for 3–12 months. >+5% → BUY | <-5% → SELL | in between → NEUTRAL
Relative Strength vs SPY
Measures how this stock has performed relative to the S&P 500. Persistent outperformance signals institutional sponsorship and sector leadership. Underperformance warns of rotation out of the stock, even in a rising market.
5-year in-sample backtest of the combined MA/RSI/MACD signal
| Signal | # Signals | Hit Rate 5d | Hit Rate 10d | Hit Rate 20d | Avg Return 5d | Avg Return 10d | Avg Return 20d |
|---|---|---|---|---|---|---|---|
| BUY | 594 | 54.5% | 55.7% | 56.7% | +0.47% | +0.87% | +1.69% |
| SELL | 385 | 51.9% | 49.9% | 53.2% | +0.21% | +0.35% | +0.22% |
Hit rate = % of BUY signals where price was higher (or SELL signals where it was lower) at the given horizon. Does not account for transaction costs. In-sample only — not a prediction of future performance.
Last 20 trading days
| Date | Close | MA | RSI | MACD | Combined |
|---|---|---|---|---|---|
| 2026-10-23 | $115.71 | HOLD | HOLD | HOLD | HOLD |
| 2026-10-26 | $113.31 | HOLD | HOLD | HOLD | HOLD |
| 2026-10-27 | $116.60 | HOLD | HOLD | HOLD | HOLD |
| 2026-10-28 | $116.87 | HOLD | HOLD | HOLD | HOLD |
| 2026-10-29 | $116.80 | HOLD | HOLD | HOLD | HOLD |
| 2026-10-30 | $120.39 | HOLD | HOLD | HOLD | HOLD |
| 2026-11-02 | $120.04 | HOLD | HOLD | HOLD | HOLD |
| 2026-11-03 | $117.59 | HOLD | HOLD | HOLD | HOLD |
| 2026-11-04 | $122.85 | HOLD | HOLD | BUY | HOLD |
| 2026-11-05 | $118.01 | HOLD | HOLD | BUY | HOLD |
| 2026-11-06 | $119.65 | HOLD | HOLD | BUY | BUY |
| 2026-11-09 | $121.89 | HOLD | HOLD | BUY | BUY |
| 2026-11-10 | $120.30 | HOLD | HOLD | BUY | BUY |
| 2026-11-11 | $122.27 | HOLD | HOLD | BUY | BUY |
| 2026-11-12 | $121.70 | HOLD | HOLD | BUY | BUY |
| 2026-11-13 | $120.97 | HOLD | HOLD | BUY | BUY |
| 2026-11-16 | $120.27 | HOLD | HOLD | BUY | BUY |
| 2026-11-17 | $119.09 | HOLD | HOLD | BUY | BUY |
| 2026-11-18 | $117.80 | HOLD | HOLD | HOLD | BUY |
| 2026-11-19 | $115.87 | HOLD | HOLD | HOLD | BUY |
| Quarter | EPS Est. | EPS Actual | Surprise | Beat? |
|---|---|---|---|---|
| 2025-12-31 | $1.92 | $1.8 | -6.1% | ✗ |
| 2026-03-31 | $1.34 | $1.81 | +35.1% | ✓ |
| 2026-06-30 | $2.15 | $3.09 | +44% | ✓ |
| 2026-09-30 | $-3.87 | $-3.6 | +6.9% | ✓ |